CureVac NV (CVAC) Peer Comparison
$4.66
$0.00 (0.00%)As on 06-Jan-2026 09:30EST
Market cap
$1,049 Mln
Revenue (TTM)
$511 Mln
P/E Ratio
7
P/B Ratio
1
Div. Yield
0 %
Edit
| CureVac NV (CVAC) | Pharvaris BV (PHVS) | ProQR Therapeutics N.V. - ADR | InflaRx N.V. - ADR | |
|---|---|---|---|---|
Market cap ($ Mln) |
1,049 | 2,414 | 191 | 192 |
Revenue (€ Mln) |
511 | -- | 19 | 0 |
Net Profit (€ Mln) |
193.64 | -171.57 | -42.32 | -29.32 |
Net Margin (%) |
37.93 | -- | -228.38 | 86,420.93 |
RoE (%) |
25.51 | -59.98 | -65.71 | -32.40 |
Price to Earnings |
6.96 | -- | -- | -- |
Price-To-Book |
1.03 | 6.77 | 2.11 | 1.19 |
Cashflow (€ Mln)
| CureVac NV (CVAC) | Pharvaris BV (PHVS) | ProQR Therapeutics N.V. - ADR | InflaRx N.V. - ADR | |
|---|---|---|---|---|
|
Cash From Operating Activities
|
101.85 | -120.13 | -36.39 | -48.56 |
|
Cash Flow from Investing Activities
|
-18.44 | -0.54 | -4.07 | 52.36 |
|
Cash from Financing Activities
|
-5.11 | 2.68 | 70.28 | 0.39 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- |
Ratios
Profitability Ratios
| CureVac NV (CVAC) | Pharvaris BV (PHVS) | ProQR Therapeutics N.V. - ADR | InflaRx N.V. - ADR | |
|---|---|---|---|---|
|
ROCE (%)
|
25.06 | -41.11 | -31.67 | -55.53 |
|
ROE (%)
|
25.51 | -41.18 | -40.40 | -56.18 |
|
ROA (%)
|
16.67 | -38.90 | -17.02 | -46.95 |
|
EBIT Margin (%)
|
-21.69 | -- | -- | -- |
|
Net Margin (%)
|
37.93 | -- | -146.86 | -27,784.96 |
|
Cash Profit Margin (%)
|
0.00 | -- | -- | -- |
Growth Ratios
| CureVac NV (CVAC) | Pharvaris BV (PHVS) | ProQR Therapeutics N.V. - ADR | InflaRx N.V. - ADR | |
|---|---|---|---|---|
|
Revenue Growth (%)
|
-6.03 | -- | 1.90 | 1.63 |
|
EBIT Growth (%)
|
-148.12 | -- | -- | -- |
|
Net Profit Growth (%)
|
78.81 | -33.06 | 1.27 | -7.96 |
|
EPS Growth (%)
|
78.23 | -0.28 | 0.05 | -0.08 |
|
Book Value Growth (%)
|
19.76 | -- | -- | -- |
Valuation Ratios
| CureVac NV (CVAC) | Pharvaris BV (PHVS) | ProQR Therapeutics N.V. - ADR | InflaRx N.V. - ADR | |
|---|---|---|---|---|
|
Price / Earnings
|
4.72 | -7.77 | -7.80 | -3.16 |
|
Price / Book Value
|
1.10 | 3.89 | 2.36 | 2.37 |
|
Dividend Yield (%)
|
-- | -- | -- | -- |
|
EV/EBITDA
|
1.52 | -5.24 | -3.22 | -2.05 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- |
Solvency Ratios
| CureVac NV (CVAC) | Pharvaris BV (PHVS) | ProQR Therapeutics N.V. - ADR | InflaRx N.V. - ADR | |
|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.18 | 0.01 |
|
Short term debt to equity ratio
|
0.00 | 0.00 | 0.05 | 0.01 |
|
Current Ratio
|
3.70 | 12.60 | 3.95 | 5.06 |
|
Quick Ratio
|
3.69 | 27.27 | 3.54 | 4.57 |
|
Interest Coverage
|
27.08 | -4,977.62 | -24.96 | -2,228.93 |
Operating Efficiency Ratios
| CureVac NV (CVAC) | Pharvaris BV (PHVS) | ProQR Therapeutics N.V. - ADR | InflaRx N.V. - ADR | |
|---|---|---|---|---|
|
Debtors to sales (%)
|
3.84 | -- | 11.10 | 1,046.71 |
|
Asset Turnover
|
0.44 | 0.00 | 0.12 | 0.00 |
|
Receivable days
|
24.71 | -- | 33.81 | 6,088.16 |
|
Inventory Days
|
43.73 | 2,694.23 | 9.39 | 1,005.64 |
|
Payable days
|
112.69 | 6,434.88 | 2,900.45 | 468.85 |
|
Cash Conversion Cycle
|
-44.25 | -- | -1,139.22 | 6,624.95 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
